Journal ArticleDOI
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson's disease.
TLDR
Savinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in patients with motor fluctuation as mentioned in this paper.Abstract:
Introduction While levodopa is still the most effective treatment for Parkinson's disease, concerns about long-term complications such as wearing-off and dyskinesia with levodopa usage remain. Areas covered : Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. This review outlines the pharmacological properties, therapeutic effects, and tolerability of safinamide as an adjunct to levodopa in patients with advanced PD. Efficacy and safety findings from double-blind and placebo-controlled clinical trials for safinamide as an adjunct therapy to levodopa for PD are summarized. Expert opinion : Safinamide was well tolerated as a treatment for PD, and there was no significant difference in the frequency and severity of adverse events between the safinamide and placebo groups. It was also suggested that safinamide had a beneficial effect on the accompanying non-motor symptoms such as PD-related pain. Safinamide may exhibit neuroprotective effects through antioxidant and anti-glutamate effects, and research on the disease-modifying effect of PD is desired in the future.read more
Citations
More filters
Journal ArticleDOI
Neuroprotective effect of Ginsenoside Re against neurotoxin-induced Parkinson's disease models via induction of Nrf2
TL;DR: The findings of the present study suggest that Re protects neurons against Rot-induced mitochondrial dysfunction and oxidative damage, at least in part, by inducing Nrf2/heme oxygenase-1 expression and activation of the dual PI3K/AKT and ERK pathways.
Journal ArticleDOI
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
TL;DR: In this paper , the long-term effects of safinamide on the course of dyskinesia and efficacy outcomes using data from a phase III, open-label 52-week study of Japanese patients with Parkinson's disease (PD) with wearing-off.
Journal ArticleDOI
Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson’s Disease: Online-Based Delphi Survey
TL;DR: In this article , the Delphi panel approach was used to summarize the opinions of panelists, and the consensus was defined as 80% or more agreement between panelists for each scenario at the final round.
Journal ArticleDOI
Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
Roongroj Bhidayasiri,Takayuki Ishida,Takanori Kamei,Ryan Edbert Husni,Ippei Suzuki,Shey-Lin Wu,Jin Whan Cho +6 more
TL;DR: Savinamide is a selective, reversible monoamine oxidase B inhibitor with demonstrated efficacy and tolerability in placebo-controlled studies and is clinically useful for patients with motor fluctuations as mentioned in this paper .
References
More filters
Journal ArticleDOI
The role of rasagiline in the treatment of Parkinson’s disease
Julie Leegwater-Kim,Elena Bortan +1 more
TL;DR: The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
Journal ArticleDOI
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Claudio Liguori,Alessandro Stefani,Roberta Ruffini,Nicola Biagio Mercuri,Mariangela Pierantozzi +4 more
Journal ArticleDOI
Impact of pain and pain subtypes on the quality of life of patients with Parkinson's disease.
Seong-Min Choi,Byeong C. Kim,Hyun-Jung Jung,Geum-Jin Yoon,Kyung Wook Kang,Kang-Ho Choi,Joon-Tae Kim,Seung-Han Lee,Man-Seok Park,Myeong-Kyu Kim,Ki-Hyun Cho +10 more
TL;DR: Multivariate regression analysis after adjusting for disease-related factors and motor characteristics showed that younger PD onset age and the high scores of part II of Unified Parkinson's Disease Rating Scale, Beck Depression Inventory, and Visual Analogue Scale were significant predictors of the poor PDQ-39 score.
Journal ArticleDOI
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
Fabrizio Gardoni,Michele Morari,James Kulisevsky,Andrea Brugnoli,Salvatore Novello,Clarissa Anna Pisanò,Carla Caccia,Manuela Mellone,Elsa Melloni,Gloria Padoani,Victoria Sosti,Silvia Vailati,Charlotte Keywood +12 more
TL;DR: Findings suggest that the striatal glutamate-modulating component of safinamide’s activity may contribute to its clinical effects, where its long-term use as levodopa add-on therapy significantly improves motor function and “on” time without troublesome dyskinesia.
Journal ArticleDOI
Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
Diego Santos García,Carmen Labandeira Guerra,Rosa Yáñez Baña,Maria Icíar Cimas Hernando,Iria Cabo López,Jose Manuel Paz Gonález,Maria Gemma Alonso Losada,Maria José Gonzalez Palmás,Cristina Martínez Miró +8 more
TL;DR: The SAFINONMOTOR study as discussed by the authors, an open-label study of the effectiveness of safinamide on non-motor symptoms in Parkinson's disease patients, was conducted in five centers from Spain and the primary efficacy outcome was the change from baseline (V1) to the end of the observational period (6 months) (V4) in the NMSS) total score.